Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Health Yuan obtains exclusive Greater China license for Fermion's analgesic drug FZ008-145, continuing to increase investment in innovative drug R&D
Published Time：
2023-11-13
Recently, Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Joincare") and Guangzhou Fermion Technology Co., Ltd. (hereinafter referred to as "Fermion") signed an exclusive license agreement in Greater China for the latter's newly developed analgesic drug FZ00-145. The innovative small molecule drug FZ008-145 is a highly selective second-generation Nav1.8 (voltage-gated sodium channel 1.8) inhibitor, with the advantages of high efficacy and non-addictive analgesia. In October this year, the IND application for FZ008-145 was submitted to the CDE.
The WHO has identified pain as the fifth vital sign in humans, following blood pressure, heart rate, body temperature, and respiration. In 2022, the global analgesic market was approximately US\$91.14 billion, while the Chinese analgesic market was approximately RMB 122.6 billion.
Mr. Yu Xiong, President of Joincare Group, said: "Joincare continues to increase investment in innovative drug R\&D. The cooperation with Fermion enriches our layout in the analgesic drug R\&D pipeline. We are optimistic about the future potential of FZ008-145 and will accelerate its clinical development in the future."
Mr. Deng Daiguo, founder of Fermion, said: "We are very pleased to cooperate with a leading pharmaceutical company like Joincare. As the second globally developed second-generation highly selective Nav1.8 inhibitor with superior PK properties, we have great expectations and confidence in its development. We believe that with Joincare's support, FZ008-145 will be fully developed and will soon bring better treatment options to patients with pain."
About Joincare
Established in 1992, Joincare Pharmaceutical Group has undergone years of steady operation and rapid development, and has now become a comprehensive pharmaceutical group focusing on innovative research. It owns two large listed companies, Joincare and Lizhu Pharmaceutical, and more than 20 major subsidiaries. Joincare has always adhered to technological innovation as its strategic foundation and aims to drive its strategy with innovation drugs and high-barrier complex preparation technology platforms. It has established a rich pipeline layout in areas with significant clinical needs, such as respiratory, analgesia, digestive tract, assisted reproduction, mental health, and oncology, forming a rich and diverse product matrix and a pipeline of drugs under research. Data shows that Joincare ranked 6th in domestic comprehensive pharmaceutical company revenue and 5th in R\&D investment in 2021, which is at a high level in the same industry.
About Fermion
Fermion Technology is an AI-driven small molecule innovative drug R\&D company. It started operations in 2019, focusing on the development of differentiated BIC/FIC products around early innovative targets in the central nervous system (CNS) and autoimmune fields. It aims to become an AI and data-driven innovative drug R\&D company. The company's independently developed Drug Studio AI drug discovery platform, with a breakthrough in target selectivity and tissue targeting, has achieved industrial application and has built an integrated AI drug R\&D solution. Since its establishment, Fermion has received recognition and support from investment institutions such as Innovation Works, Weiguang Venture Capital, Panda Capital, Challenger Capital, Tongsheng Capital, iFLYTEK Venture Capital, and Zhengxuan Investment, accumulating hundreds of millions of yuan in financing.
Source: Cailian Press
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.